Panacea Acquisition Stock Quote NUVB - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

2.30

Bid

Ask

Volume

0.00 Day's Range 0.00

0.95 52 Week Range 4.1598

Market Cap

573.264M

Previous Close

2.30

Open

Last Trade

2.29

Last Trade Time

04:23:59

Financial Volume

VWAP

Average Volume (3m)

1,522,193

Shares Outstanding

249,245,129

Dividend Yield

PE Ratio

-7.56

Earnings Per Share (EPS)

-0.3

Revenue

Net Profit

-75.8M

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's proprietary portfolio includes around six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of t... Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's proprietary portfolio includes around six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

ecor1cap.com

Headquarters

Wilmington, Delaware, USA

Founded

Panacea Acquisition Corp is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker NUVB. The last closing price for Panacea Acquisition was $2.30. Over the last year, Panacea Acquisition shares have traded in a share price range of $ 0.95 to $ 4.1598.

Panacea Acquisition currently has 249,245,129 shares outstanding. The market capitalization of Panacea Acquisition is $573.26 million. Panacea Acquisition has a price to earnings ratio (PE ratio) of -7.56.

Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024

Tumors shrank in 89% of taletrectinib-treated patients with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) who were tyrosine kinase inhibitor (TKI)-naïve and 56% of those who...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.36	-13.5338345865	2.66	2.66	2.24	2011301	2.36850514	CS
4	-0.69	-23.0769230769	2.99	3.155	2.24	1667434	2.75925216	CS
12	-0.94	-29.012345679	3.24	3.97	2.24	1522193	3.01038079	CS
26	-1.33	-36.6391184573	3.63	3.97	2.24	1525728	3.02834794	CS
52	0.96	71.6417910448	1.34	4.1598	0.95	1398066	2.47714431	CS
156	-7.71	-77.022977023	10.01	10.45	0.95	994821	3.32698651	CS
260	-7.7	-77	10	15.23	0.95	964661	4.4919987	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
OCFTOneConnect Financial Technology Co Ltd	$ 3.26 (18.55%)	21.85k
YRDYiren Digital Ltd	$ 8.50 (16.44%)	47.81k
BEKEKE Holdings Inc	$ 26.71 (14.24%)	1.26M
RDWRedwire Corporation	$ 7.31 (14.04%)	11
CNFCNFinance Holdings Limited	$ 2.18 (12.02%)	57.71k
TRPTC Energy Corporation	$ 44.31 (-8.39%)	550
NKENike Inc	$ 84.50 (-5.19%)	101.75k
LWLamb Weston Holdings Inc	$ 62.00 (-4.48%)	644
HOGHarley Davidson Inc	$ 36.50 (-4.00%)	6.27k
CWEN.AClearway Energy Inc	$ 27.44 (-3.82%)	1
NIONIO Inc	$ 7.50 (6.69%)	1.97M
BEKEKE Holdings Inc	$ 26.71 (14.24%)	1.26M
BABAAlibaba Group Holding Limited	$ 116.87 (3.66%)	687.38k
XPEVXPeng Inc	$ 13.88 (8.02%)	662.82k
RLXRLX Technology Inc	$ 1.90 (11.11%)	251.72k